Axsome Therapeutics (AXSM) Misses Q4 EPS by 28c

Axsome Therapeutics (NASDAQ: AXSM) reported Q4 EPS of ($1.41), $0.28 worse than the analyst estimate of ($1.13). Revenue for the quarter came in at $24.37 million versus the consensus estimate of $21.76 million.

For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
• UBS Reiterates Neutral Rating on Clorox (CLX) as External Challenges Persist